Melanoma Molecular Maps Projects


Targeted Therapy Database

A systematic collection of the scientific knowledge regarding the development of targeted therapy for melanoma. Since data are gathered in a computationally compatible fashion, the database can be utilized for the identification of prevalent therapeutic hypotheses based on the available evidence and for ranking treatments based on the patient's molecular profile (drug ranking system). In particular the TTD can be queried for the following purposes:

  1. To provide both basic researchers and clinical investigators with an unprecedented synopsis of the available scientific literature on the development of targeted therapy for melanoma;

  2. To obtain summaries of the current evidence on the relationship between each single molecule (or set of molecules) and the efficacy (toxicity) of a given therapeutic agent (or set of therapeutic agents);

  3. To match the patient/cancer molecular profile with the available scientific evidence on the targeted therapy of melanoma, thus developing a drug ranking system for the personalized treatment of melanoma.

Please click on the following links to open the TARGETED THERAPY DATABASE (TTD) and its User's Guide.

The second version of the Targeted Therapy Database (TTD) is now available, with more records on the personalized treatment of melanoma.


"Targeted Therapy Database (TTD): A Model To Match Patient's Molecular Profile With Current Knowledge On Cancer Biology". By: Mocellin S., Shrager J., Scolyer R., Pasquali S., Verdi D., Marincola F.M., Briarava M., Gobbel R., Rossi C., Nitti D.
PLoS One (2010), 5(8):e11965

Search the site

Risk Assessment Tools

TNM Staging System | Total Dermoscopy Score | Thin Melanoma Prognosis |

Melanoma News

Clinicopathological significance of intratumoral and peritumoral lymphocytes and lymphocyte score based on the histologic subtypes of cutaneous melanoma.
Park CK, Kim SK
Oncotarget. 2017 Jan 19;():.
PMID: 28107203 [PubMed - as supplied by publisher]

Recurrence behavior in early-stage cutaneous melanoma: pattern, timing, survival, and influencing factors.
Tas F, Erturk K
Melanoma Res. 2017 Jan 17;():.
PMID: 28099368 [PubMed - as supplied by publisher]

Genomic analysis and clinical management of adolescent cutaneous melanoma.
Rabbie R, Rashid M, Arance AM, Sánchez M, Tell-Marti G, Potrony M, Conill C, van Doorn R, Dentro S, Gruis NA, Corrie P, Iyer V, Robles-Espinoza CD, Puig-Butille JA, Puig S, Adams DJ
Pigment Cell Melanoma Res. 2017 Jan 17;():.
PMID: 28097802 [PubMed - as supplied by publisher]

NF‑κB inhibition is associated with OPN/MMP‑9 downregulation in cutaneous melanoma.
Guarneri C, Bevelacqua V, Polesel J, Falzone L, Cannavò PS, Spandidos DA, Malaponte G, Libra M
Oncol Rep. 2017 Feb;37(2):737-746.
PMID: 28075446 [PubMed - in process]

Immunoplasticity in cutaneous melanoma: beyond pure morphology.
Bosisio FM, van den Oord JJ
Virchows Arch. 2017 Jan 5;():.
PMID: 28054151 [PubMed - as supplied by publisher]

NCBI's Disclaimer and Copyright notice